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| INTRODUCTION
Patients with atrial fibrillation have long been treated with vitamin K antagonists for the prevention of cerebral embolism. The newer direct oral anticoagulants (DOACs) have been approved by the European Union since 2008. The first was dabigatran (2008), a thrombin inhibitor; this was followed by rivaroxaban (2008), apixaban (2011) and edoxaban (2015) , factor Xa inhibitors. The first approval for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) was for dabigatran in 2011 (Table S1 ). DOACs are currently recommended by the European Society of Cardiology as first-line anticoagulant treatment in NVAF, without mitral stenosis or mechanical heart valves. 1 The incidence of NVAF is estimated to be 3% in adults aged 20 or older, increasing with age, 2,3 with incidence of 12% in females and 14% in males aged over 75 years. 3 Atrial fibrillation is associated with increased cardiovascular morbidity, such as heart failure and stroke. 4, 5 Clinical trials have shown that both vitamin K antagonists and DOACs reduce stroke and mortality in AF patients. 5, 6 Utilization of DOACs for stroke prevention in NVAF and their effectiveness and safety in clinical practice have been assessed in several European countries. [7] [8] [9] [10] [11] [12] [13] However, little is known about their use beyond clinical trial conditions, especially in patients with hepatic or renal impairment. Findings from 2 studies from USA and Australia showed that inappropriate dosing occurred among patients with renal failure, and there is still uncertainty about appropriate dosing in these patients. 14, 15 In addition, the very elderly, who may be at increased risk of adverse effects with inappropriate DOAC use, are poorly represented in clinical trials. 16, 17 This cross-national comparison drug utilization study, using longitudinal data from 8 electronic health care databases in 6 European countries, uses a common protocol to characterize DOAC users in a real-world setting in order to establish the effectiveness of existing risk minimization measures and their appropriateness for the future.
Its objectives are to assess incidence of use and user characteristics, including concomitant exposure to potentially interacting medicines and rates of dose adjustment related to age or renal impairment. Datalink (CPRD), UK 27, 28 ; (viii) The Echantillon Généraliste de Bénéficiaires (EGB), France. 29 The databases characteristics are described in Table 1 .
| METHODS

| Data sources
| Study population
The study population was defined as all new users (age ≥18 years) of the DOACs of interest (dabigatran, rivaroxaban, apixaban). Only those patients with a diagnosis of NVAF (see codes in supplementary material, Table S2 ) were included. A common protocol was applied for data extraction and analysis (EU PASS Register No: 16014) for each database. 30 Results were blinded to each database lead until the analysis was completed.
New users were defined as patients initiating DOAC during the study period without any use of DOAC for at least 365 days prior to the index date (date of first DOAC prescription). Flow charts for patient inclusion for each database are shown in Figure S1 .
Patients registered in the database <1 year (365 days) before the index date and patients with a history of valvular atrial fibrillation on index date or any time prior to initiating DOACs were excluded.
Follow-up of each patient was until therapy switch, discontinuation or end of study, whichever came first. Switchers were defined as patients with a subsequent prescription of another type of (D)OAC, within the first treatment episode. Discontinuers were defined as patients who did not receive subsequent DOACs within 30 days following the theoretical end date of the prior DOAC.
As DOACs can be prescribed for indications other than NVAF, a sensitivity analysis was performed excluding patients with multiple potential DOAC indications in a ± 3 month period around the first DOAC prescription.
| Ethical approval
Participants in each country had study approval from the corresponding data owners. No other requirement was required since anonymized data were used. Additionally, the study protocol was revised and approved by an internal European Medicines Agency expert panel.
| Outcomes
The main outcome was assessing incidence of DOAC use in patients with NVAF during the study period.
Annual period incidences are estimated and defined as the number of new users during the year of interest, divided by the total number of patients in the database at midyear (1 July).
Secondary aims were to assess concomitant use of interacting drugs, defined as any prescription of a potentially interacting medicinal product as indicated in the Summary of Product Characteristics (SmPC) during the first DOAC treatment episode of each patient. A list of the concomitant interacting drugs considered in the SmPC is given in eSupplementary Material (Table S3 ). A treatment episode was defined as series of prescriptions for a DOAC, independent of dose changes, considering a gap of up to 30 days, constructed according to the method of Gardarsdottir et al. 31 Furthermore, the occurrence of dose adjustment, defined as changing from 1 tablet strength to another strength of the same active substance, was assessed during the first treatment episode.
| Analysis
The analysis is descriptive and stratified by database, individual DOAC, age group (<75, 75-79, ≥80 years), sex and calendar year.
The baseline characteristics (demographics [sex, age]), comorbidities, chronic kidney disease (CKD), renal function, laboratory data when available, hepatic impairment, previous major haemorrhagic episodes, previous cardiovascular events (see codes in Table S4 ) and
What is already known about this subject • An increase in the number of direct oral anticoagulant drug (DOAC) users with a diagnosis of nonvalvular atrial fibrillation (NVAF) has been reported since their marketing in several national/regional studies in Europe, but no cross-national comparison is available.
• The characteristics of DOAC users related to NVAF have been described but concomitant use of potentially interacting drugs is rarely reported. DOAC users are usually younger than 75 years, male and 20% of DOAC users with NVAF receive dose adjustment related to renal function.
What this study adds
• Overall DOAC incidences varied from 1.93 to 2.60 and 0.11 to 8.71 users/10 000 (2011-2015) for dabigatran and rivaroxaban, respectively, and from 0.01 to 8.12 users/10 000 (2012-2015) for apixaban.
• In 2015, the new user DOAC incidence ranged from 9 to 28/10 000 inhabitants 18 years and older in SIDIAP (Catalonia, Spain) and DNR (Denmark) databases respectively, this being higher in men than in women and in those older than 75 years. For all databases, annual period incidences, with direct standardisation by age and sex was performed based on the European standard population corresponding to each year analysed. 32 An incidence percentage change in DOAC users with NVAF is given in comparison to the first calendar year when NVAF became an approved indication for use (2012 for dabigatran and rivaroxaban, 2013 for apixaban). However, in the EGB database, DOAC percentage change was assessed for 2013-2014 since these are the calendar years with complete information. In addition, a percentage change of the standardized incidence, weighted by the database populations, was calculated from the first to the last calendar year of use.
Percentage of new DOAC users exposed to potentially interacting medication is expressed as the absolute number and percentage of the total DOAC users. Dose adjustment is expressed as the percentage of patients with adjusted dosage following the requirements of the SmPC and presented either related to change in age or renal function, as indicated in the SmPC.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 33 and CPRD) showed a range from 3.0% (Mondriaan) to 22.6% (CPRD).
DOAC users with severely or very severely reduced renal function were very uncommon in these databases. However, the proportion of unregistered information was usually high (range: 3.4% in CPRD to 77.9% in BIFAP; Table S5 ).
| Incidence
During this period, overall DOAC incidence increased ( Figure 1 ).
Standardized incidences varied from 1.93-2.60 and 0.11-8.71
users/10 000 (2011-2015) for dabigatran and rivaroxaban, respectively, and from 0.01-8.12 users/10 000 (2012-2015) for apixaban (Table 3 ). Apixaban displayed the highest standardized incidence percentage change from the first year of use following approval in NVAF to the final year studied (543.2%), followed by rivaroxaban (100.2%; Figure 1 ). This was mainly driven by a sharp increase in EGB. The standardized percentage incidence change for this first calendar year compared to the previous year was maximum in EGB period in all databases except in the DNR (Figure 2 ; Tables S6-S9 ).
The DOAC incidence increased in males and females across the study period in most databases, especially in those over 75 years, whose incidences were higher than those, men and women, younger than 75 years ( Figures S2-S4 ).
In 2015, the incidence of DOAC use ranged from 8.6 per 10 000 in SIDIAP to 27.6 per 10 000 in DNR (Table S6) , with a higher incidence in men than in women. Figure 3 shows the incidence data for all DOACs, per database and per year, for the whole study period. 
| Concomitant use of potentially interacting drugs
The proportion of patients who received an interacting drug during the first treatment episode ranged from 16 Table 5 ).
| Dose adjustment
The information on dose adjustment was available in BIFAP, SIDIAP, CPRD and EGB, varying from 4.6% in BIFAP to 15.6% in EGB. The proportion of dose adjustments related to changes in renal function or age was <1% in the 3 databases where this information was (Table S5 ). (Tables S10-S12).
| Sensitivity analysis
| DISCUSSION
Using a common protocol, we assessed the incidence of DOAC use during 2009-2015 and the characteristics of 186,405 users from 8 health care databases in 6 European countries (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . To our knowledge this is the first cross-national drug utilization study providing the incidence of DOAC use in NVAF patients at a national/regional level, across several European countries. Only a few, single country
European studies with similar inclusion criteria have been published, which only provide number of DOAC users rather than incidence figures. 10, 12, 35, 36 During the study period, the overall incidence of DOAC user increased, except in the EGB database; the individual DOAC with the highest increase was apixaban followed by rivaroxaban.
The largest incidence increase was for apixaban in the EGB. It was maximum for apixaban in the first calendar year of use in EGB 1) . The striking increase for apixaban in EGB is due to the fact that its use was very low in 2013. In 2015, the incidence of DOAC use ranged from 8.7 per 10 000 in SIDIAP to 27.6 per 10 000 in DNR, with a higher incidence in men and in those older than 75 years.
The differences in incidence across the databases might be explained by the high proportion of previous cardiovascular events in AOK, Bavarian CD and DNR databases (82.9, 76.7 and 65.0%, respectively), which may result in higher incidence of NVAF in these populations. These results correlate well with the distribution of hospital discharges for cardiovascular and cerebrovascular diseases in these countries. 37 Furthermore, differences in incidence could arise from the characteristics of the databases such as: prescription vs dispensing databases (DOACs prescribed are not necessarily dispensed), inclusion of prescriptions from specialists (although we do not expect differences in the management of NVAF between primary and specialist care since the European guidelines do not differentiate), population coverage (DNR is the only national database), different prescribing patterns in different countries, health services characteristics and their reimbursement policies, publication of guidelines (local or European), media and marketing policies. 9, 38 Several national/regional studies have reported increases in the number of DOAC users, despite the NVAF population used differing from ours. 9, 10, 39, 40 The incidence increased in both the males and females across the study period in most databases. More specifically, incidence was higher in males than in females, since NVAF is more common in men. 10, 35, 41, 42 
| Incidence of individual DOACs
Overall, rivaroxaban presented the highest incidence figures, except in the DNR, followed by apixaban and dabigatran. The initial steep increase in rivaroxaban and apixaban incidence observed in most of the databases appeared by the end of 2011 and 2012 respectively, after approval for stroke prevention. 43 This sharp increase was not observed for dabigatran as clearly in any of the databases. Other studies have shown a steep increase in users for each DOAC after their marketing. 36, 39 
| Demographic characteristics
The mean age of our study population reflected other European studies on users of DOAC with NVAF, despite varying inclusion criteria. 10, 12, 35, 36, 39, 41, 44 In line with other studies, we found that most of the users were older than 75 years, except in Mondriaan and DNR databases. 10, 12, 40 A higher proportion of males was observed in all except the German databases, similarly to other published studies. 10, 12, 35, 36, 41 The larger proportion of women in the German databases could be related to the characteristics of the population or to differences in NVAF incidence. Other studies have reported that female patients are more prevalent than males in those older than 75 or 80 years. 45, 46 
| Baseline clinical characteristics
The clinical characteristics observed are comparable to similar studies which used OAC naive or non-naive NVAF patients. 10, 35, 36 However, there is heterogeneity of the demographics and baseline characteristics across the databases. Different population coverage across the databases, as well as differences in the prevalence of cardiovascular diseases, could explain the observed differences. 37 Previous cardiovascular events were the most frequent comorbidity across all databases. The observed high proportion of previous cardiovascular events in the German databases correlates with the high percentage of cardiovascular problems observed in Germany. 37 It might also be related to the inclusion of data from medical specialists in the German databases, whereas many of the other databases in this study consider data from general practitioners only. In addition, resource allocation for German sickness funds is based on the socalled morbidity-oriented risk structure compensation scheme. Therefore, all primary and secondary diagnoses must be coded to enable appropriate calculations. 47 The low prevalence in Mondriaan database might be because only the least critical patients received DOAC from primary care, as opposed to specialists.
The unexpectedly high proportion of CKD in the AOK and Bavarian CD populations may be explained by a higher proportion of patients with cardiovascular comorbidities or the inclusion of nonspecific codes.
| Concomitant use of potentially interacting drugs
Concomitant use of drugs has been reported to be low and in very few studies. 35 Concomitant treatment with other anticoagulant drugs was present in variable proportions, around 20% in the 2 German databases, and EGB. This is of concern since these patients might have a higher haemorrhagic risk. The presence of a high cardiovascular comorbidity proportion in the German databases could partly explain a higher use of medications. Furthermore, these 3 databases include reimbursed drugs from specialist prescriptions. However, some of this use could also be related to switching to anticoagulant therapy.
The concomitant use of cardiovascular drugs has been reported in some studies, in particular antiplatelet drugs, between 11 and 30% of users 12, 36 ; similarly, antiplatelet drugs were used in 10-18% of the DOAC users in several databases in our study. Amiodarone, a strong P-glycoprotein inhibitor, was the most frequent potentially interacting drug in several databases. Lower use has been described in the OAC naïve Danish study. 36 NSAIDs have been reported in similar or somewhat lower proportions in other studies. 12, 35, 41 Certain NSAIDs are available over the counter in some countries, as well as on prescription. This, together with differing prescriber behaviours treating pain or inflammatory conditions, may account for some of the observed differences. 48
| Dose adjustment related to age or changes in renal function
The proportion of dose adjustment related to age or changes in renal function was low (<1%). However, this result should be interpreted with caution as data on renal function results were sparse (unregistered data for renal failure up to 77.9%). In fact, a study aiming to report CKD prevalence and recognition in a Swedish healthcare cohort showed that registration of CKD diagnosis was suboptimal, with only 12% of affected patients having an ICD-10 related diagnostic code. 49 However, we suspect these unregistered values are more likely to 
| Strengths
The main strength of this study is the large number of patients providing real-world data about incidence, concomitant use of potentially interacting drugs and dose adjustments. In addition, the use of a standardized protocol across the different databases supports the interpretation and comparability of results from selected countries.
Disease and drug codes were harmonized, the study results were blinded and only shared with the whole consortium after each centre had completed their analysis, avoiding some information bias and promoting independent results. The consented and broad definition of the inclusion criteria ensures the generalisability of the results as all the new users with a diagnosis of NVAF were presumably included.
In addition, the performance of a sensitivity analysis excluding patients with multiple potential DOAC indications gave similar results for most of the main variables. This supports the results of the main analysis with respect to closeness to real-life DOAC use, since several indications might be present in addition to NVAF.
| Limitations
There was large case mix in the databases, which made comparisons between countries difficult. In addition, there are differences in popu- must be considered when extending the results to the whole population. Since we used prescription, dispensing or reimbursement data that do not have complete information on actual drug intake, there might have been certain degree of drug use misclassification, common to all clinical studies, even randomized trials. In addition, drugs prescribed by physicians, other than general practitioners, could be missed when using prescribing databases as these are commonly general practice databases.
A drop in the number of patients was observed in some databases ( Figure S1 ). This may be related to the fact that DOACs can be used for a variety of diagnoses. Although some patients with NVAF may have been lost in this process, the criteria ensure that we can be certain all patients included in the analysis do indeed have NVAF.
Information on the indication associated with the prescription might also be incomplete. For example, a definite linkage between compound and indication is lacking in most of the databases hence, In conclusion, this study shows an increased incidence of use of DOACs related to NVAF in the study period across 6 European countries. In 2015, the incidence of DOAC use ranged from 8.7 per 10 000
in Spain to 27.6 per 10 000 in Denmark, with a higher incidence in men than in women, especially in patients ≥75 years. Potential use of contraindicated drugs, such as other anticoagulants, in some countries raises concerns about potential haemorrhagic risk. Finally, the proportion of dose adjustment related to changes in renal function or age deserves a more complete approach. The differences among the countries might be explained by different national or regional recommendations, prescription patterns and characteristics of the selected databases. Drug utilization studies based on several databases across different countries using a standard protocol may help to compare drug use and identify sources of variation, enabling health care decisions and supporting the rational use of medicines.
